Clinical Trial Update: Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial investigates combining alemtuzumab and rituximab to treat refractory autoimmune cytopenias, including idiopathic thrombocytopenic purpura an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: Hospital Universitario Dr. Jose E. Gonzalez | Conditions: Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune | Phase 2, Phase 3 | Status: COMPLETED